Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chinese T2D patients who are inadequate controlled (6.5 %\< HbA1C ≤9%) by metformin (≥750mg/d but ≤1000mg/d, ≥12 weeks),~Exclusion Criteria:~* Type 1 diabetes and secondary diabetes~* Acute metabolic diabetic complications within the past 3 months.~* Acute infections which may influence glucose level.~* Evidence of significant chronic diabetic complications,~* Clinically significant renal impairment and hepatic impairment patients, including history of cirrhosis or chronic hepatitis,~* FPG \> 270 mg/dl (15 mmol/l)~* Any of the following disease within the past 6 months: myocardial infarction (MI); coronary artery bypass surgery or percutaneous coronary intervention; unstable angina or stroke; Congestive heart failure (CHF)~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- metformin up titration (Type: ACTIVE_COMPARATOR): metformin 500 mg bid will be up titrated (total daily dose up to 2000 mg)
- vildagliptin add on to metformin (Type: EXPERIMENTAL): Vildagliptin 50 mg twice daily + Metformin 500mg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).